BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Pancreas Data 'Overpower'? Celgene Phase III: More Later
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Pancreas Data 'Overpower'? Celgene Phase III: More Later
Nov. 13, 2012
By
Randy Osborne
No Comments
Top-line data from a Phase III trial with Abraxane plus gemcitabine in pancreatic cancer by Celgene Corp.'s subsidiary Celgene International Sàrl suggested a benefit over the chemotherapy agent alone in overall survival (OS).
BioWorld